{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:30:16Z","timestamp":1776439816684,"version":"3.51.2"},"reference-count":20,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2025,9,16]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Patients with life-limiting illnesses often experience profound emotional and spiritual challenges that conventional palliative care treatments may not fully alleviate. Psychedelics, with their potential to facilitate deep psychological insight, offer a promising approach to enhancing end-of-life care. Despite growing interest and emerging psychiatric applications, their use in palliative settings remains poorly understood, with existing studies limited by small sample sizes and low methodological quality. This article outlines a research agenda that prioritises adequately powered randomised controlled trials with patient-centred outcome measures, with an aim to inform policy and practice change.<\/jats:p>","DOI":"10.1136\/spcare-2025-005661","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:55:12Z","timestamp":1760428512000},"page":"79-81","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Psychedelic drugs in palliative care: research agenda"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9629-0585","authenticated-orcid":false,"given":"Claire","family":"Stokes","sequence":"first","affiliation":[{"name":"Mater Health Services Brisbane, South Brisbane, Queensland, Australia"},{"name":"Mater Research Institute The University of Queensland, South Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaryan","family":"Khagram","sequence":"additional","affiliation":[{"name":"Bond University, City of Gold Coast, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Billie","family":"Metselaar","sequence":"additional","affiliation":[{"name":"University of Tasmania, Hobart, Tasmania, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9695-9109","authenticated-orcid":false,"given":"Taylan","family":"Gurgenci","sequence":"additional","affiliation":[{"name":"Mater Health Services Brisbane, South Brisbane, Queensland, Australia"},{"name":"Mater Research Institute The University of Queensland, South Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Good","sequence":"additional","affiliation":[{"name":"Mater Health Services Brisbane, South Brisbane, Queensland, Australia"},{"name":"Mater Research Institute The University of Queensland, South Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2026041707351388000_16.1.79.1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2009.0142"},{"key":"2026041707351388000_16.1.79.2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513"},{"key":"2026041707351388000_16.1.79.3","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.116"},{"key":"2026041707351388000_16.1.79.4","article-title":"Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases","volume":"9","author":"Schipper","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026041707351388000_16.1.79.5","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512"},{"key":"2026041707351388000_16.1.79.6","doi-asserted-by":"crossref","first-page":"1301960","DOI":"10.3389\/fpsyt.2024.1301960","article-title":"Palliative care patients\u2019 attitudes and openness towards psilocybin-assisted psychotherapy for existential distress","volume":"15","author":"Wang","year":"2024","journal-title":"Front Psychiatry"},{"key":"2026041707351388000_16.1.79.7","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478"},{"key":"2026041707351388000_16.1.79.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/psymed.2023.0036","article-title":"American Psychiatrists\u2019 Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey","volume":"2","author":"Barnett","year":"2024","journal-title":"Psychedelic Med (New Rochelle)"},{"key":"2026041707351388000_16.1.79.9","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00733","article-title":"Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development","volume":"9","author":"Schenberg","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026041707351388000_16.1.79.10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1177\/00048674241261779","article-title":"Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia","volume":"58","author":"Nadeem","year":"2024","journal-title":"Aust N Z J Psychiatry"},{"key":"2026041707351388000_16.1.79.11","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000000113"},{"key":"2026041707351388000_16.1.79.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2022.08.025"},{"key":"2026041707351388000_16.1.79.13","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231198466","article-title":"History repeating: guidelines to address common problems in psychedelic science","volume":"13","author":"van Elk","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"2026041707351388000_16.1.79.14","doi-asserted-by":"crossref","unstructured":"Ross S , Agrawal M , Griffiths RR , et al . Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care. Neuropharmacology 2022;216. doi:10.1016\/j.neuropharm.2022.109174","DOI":"10.1016\/j.neuropharm.2022.109174"},{"key":"2026041707351388000_16.1.79.15","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.18632\/oncotarget.13743","article-title":"Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial","volume":"8","author":"Fan","year":"2017","journal-title":"Oncotarget"},{"key":"2026041707351388000_16.1.79.16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/cncr.35010","article-title":"Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder","volume":"130","author":"Agrawal","year":"2024","journal-title":"Cancer"},{"key":"2026041707351388000_16.1.79.17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/02698811231211219","article-title":"Drug-drug interactions involving classic psychedelics: A systematic review","volume":"38","author":"Halman","year":"2024","journal-title":"J Psychopharmacol"},{"key":"2026041707351388000_16.1.79.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90343-y","article-title":"Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis","volume":"11","author":"Vizeli","year":"2021","journal-title":"Sci Rep"},{"key":"2026041707351388000_16.1.79.19","doi-asserted-by":"crossref","first-page":"1391689","DOI":"10.3389\/fphar.2024.1391689","article-title":"In vitro and in vivo metabolism of psilocybin\u2019s active metabolite psilocin","volume":"15","author":"Thomann","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026041707351388000_16.1.79.20","unstructured":"Department-of-Health-and-Aged-Care . Change to classification of psilocybin and mdma to enable prescribing by authorised psychiatrists. Canberra Australian Government; 2023. Available: https:\/\/www.tga.gov.au\/news\/media-releases\/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2025-005661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:35:50Z","timestamp":1776436550000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2025-005661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/spcare-2025-005661"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2025-005661","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]}}}